OsteoGeneX Inc., a private Delaware Corporation based in Kansas City, MO. and Lawrence KS, is an early-stage biopharmaceutical company focused on becoming a worldwide leading developer of the first true small molecule therapeutic class of bone anabolic drugs targetting SOST (Sclerostin).  These new drugs are being marketed for treatment of osteoporosis and also in combination with several orthopedic devices. 
   The Company is commercializing recent findings showing bone-forming osteoblasts can be modulated directly via a newly discovered ligand-receptor complex to regulate bone density in skeletal tissue (Ellies et al. JBMR 2006). OsteoGeneX has a  product platform which represents a new class of bone anabolic agents aimed at modulating the amount of new bone being laid down which will in turn increase the quality and strength of bone for systemic treatment of osteoporosis, and local treatment during skeletal fracture repair and other bone disorders.                                     

For further information please contact :

info@osteogenex.com

4407 NE 80 Terrace
Kansas City, MO, 64119

3514 Clinton Pkwy
Suite A164
Lawrence, KS 66047

Fax. 816.436.2441